Maury Raycroft
Stock Analyst at UBS
Total Price Targets
17
Stocks Covered
13
Sectors
Healthcare
Most Recent
Mar 9, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Maury Raycroft
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. | $98.00 | $87.86 | +11.5% | 2 | Mar 9, 2026 |
| TNGX | Tango Therapeutics, Inc. | $18.00 | $20.95 | -14.1% | 1 | Mar 5, 2026 |
| CMPX | Compass Therapeutics, Inc. | $9.00 | $1.97 | +358.0% | 1 | Mar 5, 2026 |
| BCRX | BioCryst Pharmaceuticals, Inc. | $15.00 | $9.23 | +62.4% | 3 | Oct 14, 2025 |
| TVTX | Travere Therapeutics, Inc. | $35.00 | $44.19 | -20.8% | 1 | Sep 10, 2025 |
| SGMO | Sangamo Therapeutics, Inc. | $3.00 | $0.13 | +2245.6% | 1 | Dec 31, 2024 |
| ERAS | Erasca, Inc. | $6.00 | $10.13 | -40.8% | 1 | Nov 18, 2024 |
| CUE | Cue Biopharma, Inc. | $4.00 | $30.41 | -86.8% | 2 | Nov 15, 2024 |
| PRME | Prime Medicine, Inc. | $15.00 | $3.42 | +338.0% | 1 | May 7, 2024 |
| AUPH | Aurinia Pharmaceuticals Inc. | $6.00 | $15.46 | -61.2% | 1 | May 2, 2024 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $205.00 | $297.62 | -31.1% | 1 | Jan 23, 2022 |
| NTLA | Intellia Therapeutics, Inc. | $109.00 | $13.20 | +725.8% | 1 | Jun 22, 2021 |
| CRSP | CRISPR Therapeutics AG | $172.00 | $51.72 | +232.6% | 1 | Apr 21, 2021 |
Recent Activity
- Mar 9, 2026— Set$98.00price target onDNTH(Dianthus Therapeutics, Inc.)
- Mar 5, 2026— Set$9.00price target onCMPX(Compass Therapeutics, Inc.)
- Mar 5, 2026— Set$18.00price target onTNGX(Tango Therapeutics, Inc.)
- Oct 14, 2025— Set$15.00price target onBCRX(BioCryst Pharmaceuticals, Inc.)
- Sep 10, 2025— Set$35.00price target onTVTX(Travere Therapeutics, Inc.)
- Sep 8, 2025— Set$51.00price target onDNTH(Dianthus Therapeutics, Inc.)
- Dec 31, 2024— Set$3.00price target onSGMO(Sangamo Therapeutics, Inc.)
- Nov 18, 2024— Set$6.00price target onERAS(Erasca, Inc.)
- Nov 15, 2024— Set$4.00price target onCUE(Cue Biopharma, Inc.)
- Aug 5, 2024— Set$11.00price target onBCRX(BioCryst Pharmaceuticals, Inc.)
- May 7, 2024— Set$15.00price target onPRME(Prime Medicine, Inc.)
- May 2, 2024— Set$6.00price target onAUPH(Aurinia Pharmaceuticals Inc.)
- Mar 13, 2024— Set$6.00price target onCUE(Cue Biopharma, Inc.)
- Jan 23, 2022— Set$205.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
- Aug 9, 2021— Set$19.00price target onBCRX(BioCryst Pharmaceuticals, Inc.)
- Jun 22, 2021— Set$109.00price target onNTLA(Intellia Therapeutics, Inc.)
- Apr 21, 2021— Set$172.00price target onCRSP(CRISPR Therapeutics AG)
Frequently Asked Questions
Who is Maury Raycroft?
Maury Raycroft is a stock analyst at UBS covering 13 stocks primarily in Healthcare. They have issued 17 price targets since Apr 21, 2021.
What stocks does Maury Raycroft cover?
Maury Raycroft currently covers 13 stocks, including BCRX, DNTH, CUE, TNGX, CMPX.
What is Maury Raycroft's latest price target?
Maury Raycroft's most recent price target was $98.00 on DNTH (Dianthus Therapeutics, Inc.), set on Mar 9, 2026.
What is Maury Raycroft's highest price target?
Maury Raycroft's highest issued price target is $205.00 on ALNY, set on Jan 23, 2022.
More Analysts at UBS
Coverage based on publicly published price targets. Not investment advice.